Webinar on stakeholder use of the OECD QSAR Toolbox, with insights from OECD and ECHA on its role in REACH and as an alternative to animal testing for chemical assessment.

Explore educational resources on this website to learn about safety in biotechnology and the Safe-by-Design (SbD) approach. Materials are adaptable for use in academic, research, and project contexts, aiding students and researchers in applying SbD principles.

Focuses on risk assessment of combined chemical exposures, highlighting approaches like AOPs, TK/TD models, and in silico methods for regulated products and contaminants.

Covers REACH requirements for QSAR-based adaptations, ECHA’s evaluation approach, and typical deficiencies identified in submitted QSAR studies.

A 50-hour introductory R programming and data analysis course offered in Summer 2021 at Humboldt University zu Berlin. Designed for MSc/PhD biology students with little to no coding experience.

Provides an overview of IUCLID dossier preparation and submission, detailing entities, dataset structure, validation, and the use of ECHA’s Cloud Services.

Focuses on addressing FAIR data challenges in research, highlighting persistent identifiers, metadata, and semantic interoperability through expert presentations and interactive discussions.

Concludes a week-long series of expert discussions with a plenary overview of NanoHarmony’s efforts to support OECD test guideline development, stakeholder collaboration, and long-term regulatory impact for nanosafety.

Discusses the potential of non-animal models to transform safety assessment and therapeutic development, with insights from pandemic-driven advances in regulatory science.

This webpage features Safe-by-Design educational materials developed by RIVM. Resources include an English-language course, serious games, and domain-specific tools for integrating safety into innovation processes. Materials are suitable for curricula or independent use by students and professionals.

A practical guide to navigating FAIR principles, drafting Data Management Plans, and sharing research outcomes, tailored to the needs of diverse research stakeholders.

Presents the RACE tool, supporting exposure assessment for food contaminants by comparing intake estimates with health-based guidance values.

A deep dive into FAIRsFAIR’s work on metadata, semantic interoperability, and persistent identifiers, with insights into aligning technical solutions across European research infrastructures.

This presentation focuses on the basic principles of matrix and biomarker selection in human biomonitoring, guiding participants from the identification of exposure biomarkers to their application in population studies. 

This presentation focuses on the core objectives of the HBM4EU project, providing a comprehensive overview of how each objective aligns with the project's work package structure. It highlights the strategic organisation of HBM4EU's activities and illustrates how the objectives collectively support the development of a coherent and policy-relevant human biomonitoring framework across Europe.

This presentation focuses on the role of human biomonitoring (HBM) in enhancing chemical risk assessment and supporting evidence-based policymaking. It highlights the need for reliable data on human exposure to chemicals across the EU, including variations over time, geography, and population sub-groups. The presentation also explores how HBM can inform policy by providing tools to interpret exposure data, assess health impacts, and monitor patterns and trends in chemical exposure across Europe.

This presentation focuses on exhaled breath condensate (EBC) as a biological matrix for chromium biomonitoring, explaining its production, potential applications, and the procedures for sample collection. It outlines the method developed by the Health & Safety Laboratory in the UK for chromium speciation in EBC, supported by findings from a feasibility study. 

This presentation focuses on the molecular pathways involved in the development of asbestos-related diseases, emphasising the roles of oxidative stress, DNA repair, and xenobiotic metabolism. It explores how both germline mutations and single-nucleotide polymorphisms (SNPs) within these pathways influence individual susceptibility. By understanding these mechanisms, researchers can identify clinically relevant biomarkers that support early diagnosis and risk assessment.

This presentation focuses on the fundamental terminology and principles of sampling, providing a clear overview of key concepts essential for designing and conducting human biomonitoring studies. It includes a brief introduction to the sample selection strategy developed for HBM4EU alignment studies.

This presentation provides a brief overview of key human biomonitoring (HBM) initiatives worldwide, offering insight into their scope and objectives. It includes a short introduction to the HBM4EU project, highlighting its role in coordinating efforts across Europe to advance the use of HBM in environmental health research and policymaking.

This presentation focuses on the use of blood and urine as primary biological media in HBM, outlining key characteristics of selected biomarkers in each matrix. It provides practical guidance on sample collection methods, highlighting potential pitfalls and necessary contingencies. Strategies for aliquoting and storage are discussed in detail, emphasising the importance of maintaining homogeneity in urine samples and the role of fractionation in sample pretreatment. Considerations for storage conditions, including cooling, freezing, and the use of preservatives, are also addressed to ensure sample integrity.

This presentation focuses on the concept and principles of Human Biomonitoring, specifically the classification and application of biomarkers, distinguishing between those used for exposure assessment, susceptibility evaluation, and research purposes. Highlights how the selection of specific biomarkers can provide insights into bioavailability and bioactivation over time, making them valuable tools for assessing aggregate exposure in diverse populations.

Focuses on the health risks associated with asbestos exposure, emphasizing its link to a range of diseases including asbestosis, pleural conditions, and multiple forms of cancer. Highlights malignant mesothelioma as a particularly aggressive cancer of the pleura and peritoneum, primarily caused by asbestos exposure. Discusses current challenges in diagnosing mesothelioma and the ongoing investigation into potential serum biomarkers, such as Soluble Mesothelin Related Protein (SMRP), Fibulin-3, and Survivin, for improving early detection and monitoring treatment response.

Focuses on exploring the role of gene-environment interactions in disease development, using asbestosis as a case study to illustrate the combined impact of genetic and environmental factors. Highlights findings from a nested case-control study that incorporated cumulative asbestos exposure, smoking data, and PCR-based genotyping, with logistic regression used to assess risk. Emphasises the importance of investigating how genetic factors interact with lifestyle and occupational exposures to shape disease outcomes.